首页> 外文期刊>Onkologie >Carboplatin Dosing in Children: Calculation by Different Formulae.
【24h】

Carboplatin Dosing in Children: Calculation by Different Formulae.

机译:儿童的卡铂剂量:通过不同的公式计算。

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Carboplatin dosing in children is based on renal function and there exists a wealth of formulae available for calculating the body surface area (BSA), the glomerular filtration rate (GFR), and the carboplatin dose. Patients and Methods: A fictitious group of children with different ages and body builds was 'constructed'. For comparison of formulae, bias and precision were assessed. Results: BSA calculations according to DuBois-DuBois, Gehan-George, Mosteller, and Boyd showed good agreement. GFR calculations according to the weight-based Cole formula and the Leger formula gave comparable results. Regarding GFR in young children, the weight-and creatinine-based Cole and the Schwartz formula showed clear differences. Again, carboplatin dose calculations according to Marina, Newell, and Chatelut are comparable. Moreover, the precision of the creatinine measurement has a clear influence on the result of the dose calculation. Conclusions: The choice of the GFR formula is more important for the carboplatin dose calculation compared to the BSA or dose equation. GFR calculations in children show marked, age-dependent variations. A sequence of multiple calculation steps (especially for the Schwartz and Marina formulae) may lead to considerable uncertainty and proneness to error in the clinical routine. In high-risk patients, GFR should be measured precisely and complemented by therapeutic drug monitoring.
机译:背景:小儿卡铂的剂量基于肾功能,并且存在大量可用于计算体表面积(BSA),肾小球滤过率(GFR)和卡铂剂量的公式。患者和方法:虚构了一组不同年龄和体型的儿童。为了比较公式,评估了偏差和精度。结果:根据DuBois-DuBois,Gehan-George,Mosteller和Boyd进行的BSA计算显示出良好的一致性。根据基于权重的Cole公式和Leger公式的GFR计算得出了可比的结果。关于幼儿的GFR,基于体重和肌酐的Cole和Schwartz配方奶粉显示出明显的差异。同样,根据Marina,Newell和Chatelut的卡铂剂量计算是可比的。此外,肌酐测量的精度对剂量计算的结果有明显的影响。结论:与BSA或剂量方程相比,GFR公式的选择对于卡铂剂量的计算更为重要。儿童的GFR计算显示明显的,年龄相关的变异。一连串的多个计算步骤(尤其是Schwartz和Marina公式)可能会导致相当大的不确定性,并且在临床程序中容易出错。在高危患者中,应精确测量GFR,并辅以治疗药物监测。

著录项

  • 来源
    《Onkologie》 |2011年第2期|共7页
  • 作者

    Boos J;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 ger
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号